Under construction – not a live service
Sign in
Taking people in FrancePhase 4

Long-term safety of pirtobrutinib in people with leukemia or lymphoma

Checks long-term safety of pirtobrutinib in adults with CLL or lymphoma who finished earlier studies.

Key facts

Who runs it
Eli Lilly and Company
Where
Nantes, FranceSee the siteAlso in 7 other countries, 35 sites
Trial code
Registry title
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Status
Recruiting
Phase
Phase 4
People taking part
787 people, planned
Started
20 May 2025
Expected to end
Dec 2032
Type of study
Interventional
Treatments tested
  • Pirtobrutinib
Record updated
2 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who took part in an earlier Lilly-sponsored study of pirtobrutinib. It checks long-term safety and lets them keep getting treatment or follow-up visits.

Age
18 years and older
Sex
Women and men can join.
Earlier treatment
The person must be taking part in an earlier Lilly-sponsored clinical study of pirtobrutinib.

Main reasons for not taking part

  • Exclusion rules are set separately for each earlier study (in its own appendix).

The registry criteria, word for word

Show the criterionShow less

Who can take part

  • Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib

Where in France

Also in 7 other countries, 35 sites

  • CHU de Nantes - Hôtel DieuNantes, FranceContact: Thomas Gastinne (principal investigator)Taking people

About the trial

What the trial wants to find out

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

The group in the trial

  • JZ01 PirtobrutinibTreatment being tested

    Participants receive pirtobrutinib as defined in the originator study (LOXO-BTK-18001/J2N-OX-JZNA). Pirtobrutinib administered orally.

    Treatment: Pirtobrutinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Plain-language title
Long-term safety of pirtobrutinib in people with leukemia or lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 March 2026